AbbVie, Lilly, Roche and Takeda have demonstrated strong interest in licensing innovator oligonucleotides for CNS indications ...

Actio Biosciences has closed a Series B financing round, raising $66m for advancing the genetics-driven small molecule ...

While the outlook for vaccines in the US looks bleak under Trump's administration, the UK is pressing ahead with securing its ...

BioOrbit CEO Dr Katie King said that pre-clinical studies of the crystals produced in space could start as early as 2026.

Draig Therapeutics has secured £107m ($140m) in an oversubscribed Series A financing round to treat major neuropsychiatric ...

NICE said it made every effort to support reimbursement for Kisunla and Leqembi, but found the medicines are “not good value ...

The FDA has approved Gilead Sciences' injectable product, Yeztugo (lenacapavir), as a pre-exposure prophylaxis (PrEP) against ...

Orion Corporation has broadened its partnership with Glykos, focusing on the development of antibody-drug conjugates (ADCs).

FDA Commissioner Dr Marty Makary tried to allay industry concerns about recent cuts and outlined his agenda for the future.

Tisento Therapeutics has received fast track designation from the US Food and Drug Administration (FDA) for zagociguat.

The FDA launched a new Priority Review program, as uncertainty persists for the existing programme for paediatric disorders.

The test is currently available in private healthcare facilities but there are hopes it may be adopted by the NHS.